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The male genital tract is a potential site of viral persistence. Therefore, adequate concentrations of antiretrovirals are required to
eliminate HIV replication in the genital tract. Despite higher zidovudine (ZDV) and lamivudine (3TC) concentrations in seminal
plasma (SP) than in blood plasma (BP) (SP/BP drug concentration ratios of 2.3 and 6.7, respectively), we have previously re-
ported lower relative intracellular concentrations of their active metabolites, zidovudine triphosphate (ZDV-TP) and lamivu-
dine triphosphate (3TC-TP), in seminal mononuclear cells (SMCs) than in peripheral blood mononuclear cells (PBMCs) (SMC/
PBMC drug concentration ratios of 0.36 and 1.0, respectively). Here, we use population pharmacokinetic (PK) modeling-based
methods to simultaneously describe parent and intracellular metabolite PK in blood, semen, and PBMCs and SMCs. From this
model, the time to steady state in each matrix was estimated, and the results indicate that the PK of 3TC-TP and ZDV-TP in
PBMCs are different from the PK of the two in SMCs and different for the two triphosphates. We found that steady-state condi-
tions in PBMCs were achieved within 2 days for ZDV-TP and 3 days for 3TC-TP. However, steady-state conditions in SMCs were
achieved within 2 days for ZDV-TP and 2 weeks for 3TC-TP. Despite this, or perhaps because of it, ZDV-TP in SMCs does not
achieve the surrogate 50% inhibitory concentration (IC50) (as established for PBMCs, assuming SMC IC50  PBMC IC50) at the
standard 300-mg twice-daily dosing. Mechanistic studies are needed to understand these differences and to explore intracellular
metabolite behavior in SMCs for other nucleoside analogues used in HIV prevention, treatment, and cure.
Ongoing viral replication in the male genital tract poses chal-lenges for HIV prevention, treatment, and cure. From a pre-
vention standpoint, virus in semen remains a major vector of HIV
transmission; in serodiscordant heterosexual couples, early initi-
ation of antiretroviral (ARV) treatment in the infected partner,
with maintained suppression of peripheral HIV RNA, can reduce
the rate of transmission by 96%, compared to delaying ARV treat-
ment until later in the course of disease (1). The single linked HIV
transmission event in the HPTN052 early treatment arm was from
an infected male to his uninfected female partner within approx-
imately 29 days of starting ARV therapy (1, 2). Additionally, to
date, evidence strongly suggests that early, effective antiretroviral
treatment limits the size of the viral reservoir, providing the best
chance of HIV eradication (3). Finally, ongoing viral replication
has been demonstrated in sanctuary sites, such as the central ner-
vous system, gut-associated lymphoid tissue, and the genital tract,
where antiretroviral concentrations may differ from those seen
systemically (reviewed in reference 4). Since HIV eradication will
not be possible with ongoing viral replication in sanctuary com-
partments, it is important to select ARVs with optimized pharma-
cokinetic (PK) and pharmacodynamic profiles to control viral
replication in the male genital tract, as well as other sanctuary sites.
We have previously published a noncompartmental pharmacoki-
netic analysis of zidovudine (ZDV) and lamivudine (3TC) in blood
plasma (BP) and seminal plasma (SP), and their active triphosphate
analogs zidovudine triphosphate (ZDV-TP) and lamivudine triphos-
phate (3TC-TP) in peripheral blood mononuclear cells (PBMCs) and
seminal mononuclear cells (SMCs) (5). With this unique, rich data
set, our goals for this analysis were as follows: (i) to create a PK model
to describe the distribution of ZDV and 3TC in BP and SP, (ii) to
describe the rate of formation and elimination of ZDV-TP and
3TC-TP in SMCs in relation to PBMCs, and (iii) to estimate the time
to steady state and theoretical effective concentrations in SMCs.
MATERIALS AND METHODS
Study design. The data used to develop this model were extracted from a
previously published study of 13 HIV-infected men receiving 300 mg of
ZDV and 150 mg of 3TC twice daily as part of their ARV regimen (5). This
study’s protocol was approved by the Biomedical Institutional Review
Board of the University of North Carolina at Chapel Hill. Sample collec-
tion was comprised of one intense sampling period and three sparse sam-
pling periods. During the intense sampling period, blood was collected
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predose and 0.5, 1, 2, 4, 6, 8, and 12 h postdose, and semen was collected
predose and 12 h postdose. The sparse sampling periods were conducted
within the following 2 weeks, and in this period, one semen sample and
one blood sample were collected at 3, 6, and 9 h postdose. ZDV and 3TC
were measured in blood and seminal plasma, while ZDV-TP and 3TC-TP
were measured in PBMCs and SMCs using validated liquid chromatogra-
phy coupled to tandem mass spectrometry (LC-MS/MS) methods (6, 7).
Model development. Each drug and its metabolite were comodeled,
using the first-order conditional estimation with interaction method in
NONMEM version 7.3 (ICON Development Solutions, Hanover, MD). R
version 3.1.0 (https://www.r-project.org) was used for data management
and graphical analysis. Model selection was based on decreases in objective
function and the likelihood ratio test (alpha  0.05), goodness-of-fit plots,
and visual predictive checks of predicted concentrations versus observed con-
centrations. All concentrations were converted to nanograms/milliliter, using
an estimate for the volume of mononuclear cells of 282 fl/cell (8), and con-
centrations were log transformed for modeling purposes.
One- and two-compartment models were evaluated for each parent
drug’s disposition in BP, and then the PBMC compartments were added
to describe triphosphate concentrations. Once this model was stabilized,
the SP, and then the SMC compartments were added in a sequential man-
ner. Several methods of linking the matrices were tested, including one-
way and two-way transit, fractional clearances, and nonlinear disposition.
Within each modeling step, parameters were initially added to the model
with interindividual variability (IIV) and then evaluated for contribution
to model fit. Initial estimates were based on biological plausibility and
model parameter exploration in Berkeley Madonna 8.3.18 (University of
California at Berkeley, Berkeley, CA). Berkeley Madonna is an easy-to-
use, flexible, general differential equation solver with graphics capabili-
ties, allowing one to determine the effects of various values of model
parameters on model predictions compared to the observed data. Certain
unidentifiable model parameters, such as the fraction of drug transferred
to PBMCs and SP, were fixed to biologically plausible values, using this
program (9). Each matrix in each model used a separate proportional-
error term to describe residual variability, and as these samples were col-
lected at the same time, correlation between these error terms was estimated.
Finally, interoccasion variability was tested for inclusion on relevant param-
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FIG 1 Schematic of lamivudine (3TC) and zidovudine (ZDV) pharmacoki-
netic models. The models differ only in the addition of a second blood plasma
(BP) compartment for ZDV, shown in the box outlined by gray dashed lines.
For 3TC, BP was described using one compartment with first-order absorption
(ka, absorption rate constant) and first-order elimination (CLt, clearance; de-
fined as total body clearance [CLtt] minus clearance from blood to seminal
plasma [CLs] minus clearance from blood to PBMCs [CLm]; CLt  CLtt  CLs
 CLm). For ZDV, BP was described as using two compartments (CLd, distri-
butional clearance), with the same absorption and elimination parameters.
Drug transferred from BP to seminal plasma (SP) via the clearance parameter
CLs, which is defined as total body clearance (CLtt) multiplied by the fraction
to semen (Fs) (CLs  CLtt  Fs). Transfer of drug to these compartments was
assumed to be unidirectional. Disposition in SP was described as a one-com-
partment system with first-order clearance (CLs) to the seminal mononuclear
cells (SMCs) and seminal volume (Vs). Drug transferred from SP to SMCs via
the clearance parameter CLsp and SMCs was described as a one-compartment
system with first-order clearance (CLsmc) and volume (Vsmc). Drug transferred
from BP to peripheral blood mononuclear cells (PBMCs) via the clearance
parameter CLm, which is defined as total body clearance (CLtt) multiplied by
the fraction metabolized (Fm) (CLm  CLtt  Fm). Disposition in PBMCs was
described as a one-compartment system with first-order clearance (CLpbmc)
and volume (Vpbmc).
TABLE 1 Estimated model parameters for zidovudine (ZDV) and
lamivudine (3TC)
Parameter(s)a




ka (1/h) 1.20 (0.68 to 10.7) 1.26 (0.857 to 2.36)
CLtt (liter/h) 231 (199 to 299) 31.3 (25.9 to 34.8)
Vc (liter) 69.5 (31.2 to 368) 138 (113 to 155)
CLpbmc (10
2 liter/hour) 1.86 (1.63 to 2.08) 2.44 (1.73 to 3.16)
CLsp (10
3 liter/hour) 7.83 (7.03 to 8.84) 0.303 (0.214 to 0.435)
CLsmc (10
4 liter/hour) 450 (332 to 606) 0.680 (0.470 to 1.17)
Vp (liter) 190 (124 to 991)
CLd (liter/hour) 60.4 (22.1 to 78.2)
Fm 1  10
4 (fixed) 0.1 (fixed)
Fs 1  10
4 (fixed) 0.01 (fixed)
Interindividual variability
(CV%)
ka 0.548 (0.548 to 52.1)
CLtt 21.6 (7.04 to 27.1)
Vc 162.2 (22.2 to 217) 17.8 (3.81 to 26.2)
CLpbmc 17.4 (0.224 to 26) 45.3 (19.8 to 60.6)
CLsp 20.3 (0.167 to 26.8)
CLsmc 61.1 (0.707 to 77.3) 59.7 (41.2 to 70.4)
CLtt and Vc (covariance,
102)
3.84 (0.420 to 6.80)
Interoccasion variability
(CV%)
ka 118.7 (86 to 158)
CLtt 49.3 (0.265 to 62.4) 5.00 (1.25 to 25.3)
Vc 2.50 (0.706 to 25.8)
ka and CLtt (covariance,
102)
5.61 (11.0 to 16.3)
ka and Vc (10
2) 2.08 (12.6 to 19.0)
CL and Vc (10
3) 1.10 (0.680 to 63.0)
Residual variability (CV%)
BP 43.0 (32.9 to 63.5) 29.9 (24.0 to 32.5)
PBMCs 29.9 (22.3 to 38.1) 56.2 (41.4 to 73.9)
SP 57.5 (44.7 to 70.3) 41.4 (32.9 to 49)
SMCs 30.7 (22.7 to 43.9) 41.5 (19.5 to 64.5)
BP and PBMCs
(covariance, 102)
1.42 (8.80 to 10.6) 3.16 (1.85 to 8.63)
BP and SP (102) 24.7 (0.236 to 35.4) 2.84 (0.814 to 8.64)
SP and PBMCs (102) 0.96 (17.2 to 15.4) 23.3 (9.64 to 30.4)
BP and SMCs (102) 11.0 (10.4 to 13.8) 6.99 (12.4 to 8.22)
PBMCs and SMCs
(102)
5.93 (1.82 to 11.6) 13.7 (30.6 to 28.6)
SP and SMCs (102) 14.1 (7.66 to 18.5) 10.5 (24.1 to 17.0)
a Parameters are depicted in Fig. 1 and defined in the Fig. 1 legend and in the text. Vp,
volume of distribution in the peripheral compartment.
b Values are presented as geometric means with bootstrapped 95% confidence intervals
(95% CI) or coefficient of variance (CV%).
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eters, as subjects had contributed samples on multiple occasions. Due to the
small number of relatively homogenous subjects (all men, equal numbers of
African-Americans and Caucasians, age range from 28 to 48 years), covariate
analysis of demographic descriptors that could influence pharmacokinetics
was not performed. Bootstrap analysis (100 replicates) was used to validate
parameter estimates and model stability.
Simulations for visual predictive checks, estimation of time to steady state,
and approach to theoretical 50% inhibitory concentrations (IC50s) were per-
formed in NONMEM 7.3. The IC50s were obtained from the literature (10)
and prescribing information (11) and are as follows: 115 ng/ml for 3TC, 554
fmol/106 cells for 3TC-TP, 13 ng/ml for ZDV, and 269 fmol/106 cells for
ZDV-TP. Concentrations provided in the original references as molar units
were converted using a standard assumption of cellular volume of 282 fl/cell
as described above. Simulations for visual predictive checks assumed that all
observations were collected during the same occasion.
RESULTS
Final model and validation. The final models for each drug are
shown in Fig. 1. Briefly, 3TC in BP was best described using one
compartment, while ZDV in BP was best described using two
compartments (central and peripheral), both with first-order ab-
sorption and first-order elimination. For both drugs, a total sys-
temic clearance (CLtt) was estimated, and the BP clearance (CLt)
was defined as the total systemic clearance minus the clearance to
the PBMCs (CLm  CLtt  Fm where CLm is clearance from blood
to PBMCs and Fm is the fraction metabolized), minus the clear-
ance to the SP (CLs  CLtt  Fs where CLs is clearance to semen
and Fs is the fraction to semen). CLm and CLs include formation of
triphosphate metabolite (three-step phosphorylation) and entry
into the monocytic compartments. PBMC pharmacokinetics were
described with a single compartment; SP pharmacokinetics were
described with a compartment linked by a first-order clearance
parameter to a compartment describing the SMC concentrations.
Triphosphates exited both the SMC and PBMC compartments
with first-order clearance terms.
Table 1 lists the model parameter values for each drug, and the
nonparametric 5 to 95% bootstrap confidence intervals for each pa-
rameter. Exponential error models were used to describe interindi-
vidual variability, and proportional error models were used to de-
scribe residual variability. Interoccasion variability was placed on the
absorption rate constant (ka), CLtt, and volume of distribution in the
central compartment (Vc) for 3TC and on CLtt for ZDV.
Figures 2a to d and 3a to d show the visual predictive checks for
ZDV/ZDV-TP and 3TC/3TC-TP, respectively, in the four matrices.
The solid lines indicate the prediction median, and the shaded region
is the 90% confidence interval. The data points are the observations
used to develop the model. These graphs indicate that each model
does a reasonable job of describing the observed data.
a b
c d
FIG 2 Visual predictive checks for zidovudine (ZDV) (a and c) and zidovudine triphosphate (ZDV-tp) (b and d) in blood plasma (a), PBMCs (b), seminal
plasma (c), and seminal mononuclear cells (d). The solid line is the median of the simulated data set, the dashed lines encompassing the dark gray region represent
the 75th and 25th percentiles of the simulations, and the dotted lines encompassing the light gray regions represent the 95th and 5th percentiles of the simulations.
The black dots are the observed data points.
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Figures 4a to d and 5a to d show the simulated concentration-
time profiles as each drug approaches steady state from a first dose
in each matrix. As expected for the parent drugs, given their short
BP and SP half-lives, steady state is achieved quickly, after approx-
imately 2 doses (1 day). For the longer-lived triphosphate metab-
olites, we observed differences in approach to steady state between
PBMCs and SMCs and between 3TC-TP and ZDV-TP. As previ-
ously observed, the ZDV-TP exposures in SMCs were 36% of
those in PBMCs, and here, the time to steady state was 30%
shorter (2 days, based on median simulation values) compared to
PBMCs (3 days). The estimated half-lives for ZDV-TP in PBMCs
and SMCs were 20 h and 14 h, respectively. For 3TC-TP, although
PBMC and SMC exposures were similar at steady state, the ap-
proach to steady state was quite different. In PBMCs, the 3TC-TP
time to steady state was 3 days (similar to ZDV-TP in PBMCs).
However, the SMC concentrations accumulated over 20 days be-
fore reaching steady-state conditions. The estimated half-lives for
3TC-TP in PBMCs and SMCs were 5 h and 159 h, respectively.
Also shown in Fig. 4 and 5 are the IC50s for wild-type HIV in BP
and PBMCs. Since the targets in SP and SMCs are unknown, BP
and PBMC values were used as surrogates, assuming the same
general relationship between parent and metabolite concentra-
tions (12, 13). Median 3TC and 3TC-TP concentrations achieve
and exceed IC50s in all matrices with the first dose. ZDV is well
above the targets in BP and SP, but median predicted concentra-
tions in PBMCs and SMCs do not reach the surrogate target. As-
suming dose linearity for ZDV and ZDV-TP, simulations of
higher ZDV doses (data not shown) suggest that 450 to 600 mg
twice daily would be required for at least half of the simulated
profiles to reach the PBMC target at steady state and that 750 to
900 mg twice daily would be required for at least half of the sim-
ulated profiles to reach the SMC target at steady state.
DISCUSSION
The penetration of the parent drugs studied here, 3TC and ZDV,
into SP has been studied by several groups, and consistently found
to exceed concentrations in BP (reviewed in reference 14). Their
active intracellular metabolite concentrations are less well studied,
but work thus far indicates that the presence of the parent drug in
the SP does not guarantee corresponding high levels of phosphor-
ylation (5). Although penetration of parent drug into the SP can
be predicted by plasma protein binding (15), the correlates and
predictors of phosphorylation in SMCs are currently unknown.
The phosphorylation process is driven by stepwise kinase activity,
and the competition between the drug triphosphate and the en-
dogenous nucleotide that it mimics (dCTP for 3TC and deoxythy-
a b
c d
FIG 3 Visual predictive checks for lamivudine (3TC) (a and c) and lamivudine triphosphate (3TC-tp) (b and d) in blood plasma (a), PBMCs (b), seminal plasma
(c), and seminal mononuclear cells (d). The solid line is the median of the simulated data set, the dashed lines encompassing the dark gray region represent the
75th and 25th percentiles of the simulations, and the dotted lines encompassing the light gray regions represent the 95th and 5th percentiles of the simulations.
The black dots are the observed data points.
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midine triphosphate for ZDV) for incorporation into the viral
DNA produced by reverse transcriptase drives efficacy (16). The
anabolic process for the triphosphates is fairly well described in
PBMCs (16) but is largely unknown in SMCs. Our work suggests
that these basic cellular processes differ in ways that result in dif-
ferent PK profiles in SMCs for nucleoside reverse transcriptase
inhibitors and that each agent with clinical relevance must be
studied to elucidate individual mechanisms. Differences in cellu-
lar activation state (17), the specific cell populations that comprise
the mononuclear cell pool in semen and blood (18), drug metab-
olism (i.e., ZDV glucuronidation) (19), and kinase activities (16)
may contribute to these differences. For both PBMCs and SMCs,
the catabolic process for the triphosphate metabolites is not well
described, although previous modeling work combining ex vivo
and in vivo studies of 3TC-TP in PBMCs suggests that catabolism
of 3TC-TP in PBMCs is less likely to be a critical determinant of
disposition and more likely to be dependent on the total 3TC
parent and metabolite pools within the cell (20).
Using antiretrovirals that achieve suppressive concentra-
tions in the genital tract are the best chance to prevent trans-
mission and limit reservoir establishment early in infection.
Although ZDV-TP in SMCs achieves steady state rapidly, its
median concentrations are well below the PBMC IC50. Consis-
tent with this, ZDV-resistant viral transmission has been re-
ported (21). Conversely, 3TC-TP has a very long half-life in
SMCs, potentially related to the differences in pharmacology,
cell composition, and overall pool of 3TC and its metabolites in
SMCs detailed above, and yet concentrations are well above the
IC50. It is currently unknown whether these in vitro IC50 esti-
mates in PBMCs are meaningful in semen, but they do provide
some insight into relevant concentrations. 3TC remains a
mainstay of therapy in the fixed-dose combinations used ex-
tensively in the developing world, with zidovudine a potential
alternative to tenofovir (22). As HIV-infected patients in the
developing world are more likely to be infected for longer prior
to beginning antiretrovirals, thus allowing the establishment of
the viral reservoir, the ability of these drugs to suppress virus in
reservoir compartments is paramount to achieving cure.
Tenofovir disoproxil fumarate (TDF) and emtricitabine (FTC)
have largely replaced 3TC and ZDV as the nucleoside backbone of
HIV treatment in the United States, although 3TC is included in
the recommended first-line regimen of 3TC-abacavir-dolutegra-
vir (Triumeq; ViiV Healthcare, Research Triangle Park, NC) for
antiretroviral-naive patients able to safely receive abacavir (23).
To our knowledge, FTC and its triphosphate have not been stud-
ied in SP or SMCs; evidence in the female genital tract suggests
a b
c d
FIG 4 Simulations from the first dose to steady state for zidovudine (ZDV) (a and c) and zidovudine triphosphate (ZDV-tp) (b and d) in blood plasma (a), PBMCs (b),
seminal plasma (c), and seminal mononuclear cells (d). The solid line is the median of the simulated data set, the dashed lines encompassing the dark gray region
represent the 75th and 25th percentiles of the simulations, and the dotted lines encompassing the light gray regions represent the 95th and 5th percentiles of the
simulations. The dashed-and-dotted horizontal line references literature IC50 values in each matrix (13 ng/ml for ZDV and 269 fmol/10
6 cells for ZDV-tp).
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that parent FTC exposure would be similar to 3TC (24), but be-
havior of the triphosphate in SMCs is unknown. The model de-
veloped for 3TC could be applied to FTC disposition in the male
genital tract, if such data were available. The penetration of TDF
into SP has been studied by several groups (25, 26), but only one
paper has examined its active diphosphate form in SMCs (27).
Vourvahis and colleagues found 9-fold-higher concentrations of
the diphosphate in SMCs at a first dose of TDF monotherapy, and
17-fold-higher concentrations in SMCs at steady state; in SMCs,
these concentrations exceed the proposed IC90 in PBMCs (16
fmol/106 cells) (28) by at least 10-fold. Models have not been
applied to these data, to our knowledge; tenofovir alafenamide, an
alternate formulation of tenofovir designed specifically to increase
PBMC tenofovir diphosphate concentrations while decreasing BP
tenofovir concentrations, will soon be approved in the United
States and is likely to replace the tenofovir disoproxil fumarate
formulation in the developed world (29, 30). The models de-
veloped here could also be applied to PBMC and SMC tenofo-
vir diphosphate concentrations in subjects receiving these for-
mulations. Our group plans to generate these data for FTC,
tenofovir disoproxil fumarate, and tenofovir alafenamide in
the future.
The ability to study viral dynamics and reservoir formation
in the genital tract, in concert with pharmacology, has ad-
vanced substantially since this work was performed (2000 to
2003), and thus, such virologic data are not available to pair
with this pharmacokinetic data for a full exploration of mech-
anistic implications. Given these findings of differing pharma-
cology in SP and SMCs between nucleosides, determining the
pharmacologic mechanisms of phosphorylation and predictors
of ARV behavior for clinically used agents in concert with viral
dynamics in the male genital tract is necessary for optimizing
drug therapy for HIV treatment as prevention and eradica-
tion.
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FIG 5 Simulations from the first dose to steady state for lamivudine (3TC) (a and c) and lamivudine triphosphate (3TC-tp) (b and d) in blood plasma (a),
PBMCs (b), seminal plasma (c), and seminal mononuclear cells (d). The inset in panel d shows the full approach of 3TC-tp to steady state over 28 days in seminal
mononuclear cells. The solid line is the median of the simulated data set, the dashed lines encompassing the dark gray region represent the 75th and 25th
percentiles of the simulations, and the dotted lines encompassing the light gray regions represent the 95th and 5th percentiles of the simulations. The dashed-
and-dotted horizontal line references literature IC50 values in each matrix (115 ng/ml for 3TC and 554 fmol/10
6 cells for 3TC-tp).
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